OR-54: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria

OR-54: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria

Hypertensive patients with diabetes have increased likelihood of proteinuria, a predictor of end-stage renal disease. This 24-week, double-blind study compared the renal and antihypertensive effects and the tolerability of eplerenone (EPL), a selective aldosterone blocker, enalapril (ENAL), an ACE i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hypertension 2002-04, Vol.15 (S3), p.24A-24A
Hauptverfasser: Epstein, M., Buckalew, V., Martinez, F., Altamirano, J., Roniker, B., Kleiman, J., Krause, S.
Format: Artikel
Sprache:eng
Schlagworte:
Antiproteinuric
Diabetic Hypertensive
Eplerenone
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hypertensive patients with diabetes have increased likelihood of proteinuria, a predictor of end-stage renal disease. This 24-week, double-blind study compared the renal and antihypertensive effects and the tolerability of eplerenone (EPL), a selective aldosterone blocker, enalapril (ENAL), an ACE inhibitor, and EPL+ENAL combination therapy in hypertensive patients with diabetes and proteinuria. Diabetic type 2 patients with mild-to-moderate hypertension (DBP ≥95 mmHg and
ISSN:0895-7061
1941-7225
1879-1905
DOI:10.1016/S0895-7061(02)02333-6